How hayfever works: The Full Evidence

What is the evidence for intranasal phototherapy (red/near-infrared light) in allergic rhinitis?

What the research says

Intranasal phototherapy using red and near-infrared light (photobiomodulation therapy) demonstrates clinically meaningful reductions in core allergic rhinitis symptoms—rhinorrhea, sneezing, nasal pruritus, and obstruction—with large effect sizes reported in a 2022 meta-analysis (ES ranging from -1.10 to -1.35) and significant improvements in peak nasal inspiratory flow and rhinitis control scores in a 2024 double-blind RCT (n=62). Evidence spans nearly three decades of study from 1997 to 2025, consistently showing superiority over sham/placebo controls with a favorable safety profile. However, the overall evidence base remains constrained by small sample sizes, high heterogeneity (I² >91%), and a lack of standardized treatment protocols across trials.

How it works

Red and near-infrared photons are absorbed by mitochondrial chromophores (particularly cytochrome c oxidase), triggering anti-inflammatory cascades that induce apoptosis of activated immune cells, suppress pro-inflammatory mediators including IgE and IL-4, inhibit mast cell histamine release, and promote mucosal remodeling in the nasal epithelium. These immunomodulatory effects are thought to be more pronounced in perennial allergic rhinitis where chronic inflammatory changes in the nasal turbinates provide a more sustained therapeutic target.

---

How effective are nasal filters and barrier devices at reducing pollen inhalation?

What the research says

Nasal filters and barrier devices demonstrate meaningful reductions in allergic rhinitis symptoms during pollen exposure, with a double-blind RCT reporting a 40% median reduction in Total Nasal Symptom Scores and marked reductions in individual symptoms such as sneezing (83%) and runny nose (53%) compared to placebo. A 2020 systematic review and meta-analysis supports these findings, indicating that barrier protection measures broadly improve AR symptom outcomes. Emerging devices such as bionic nasal hair/blocking gel masks show high experimental filtration efficiency (100% at 15 minutes), though these require validation in clinical settings.

How it works

Nasal filters and barrier devices physically intercept airborne pollen particles before they contact the nasal mucosa, preventing allergen binding to IgE-sensitized mast cells and the subsequent inflammatory cascade that drives rhinitis symptoms. Novel hybrid devices augment mechanical filtration with chemical adhesion via blocking gels, potentially improving capture efficiency across a wider range of particle sizes.

---

What is the evidence for acupuncture in treating hayfever?

What the research says

Multiple systematic reviews and meta-analyses indicate that acupuncture produces statistically significant improvements in nasal symptom scores and quality of life in allergic rhinitis patients compared to sham acupuncture or no treatment, with the 2022 meta-analysis of 30 RCTs (n=4413) providing the most robust pooled evidence to date. However, evidence specific to seasonal allergic rhinitis (hayfever) remains limited, as most trials focus on perennial allergic rhinitis, and methodological quality across studies is variable. The overall direction of evidence is positive but not definitive, particularly for seasonal presentations.

How it works

Acupuncture is proposed to modulate immune responses by downregulating IgE-mediated inflammatory pathways, reducing pro-inflammatory cytokines, and suppressing mast cell degranulation in nasal mucosa, thereby decreasing nasal hyperreactivity. Neurological modulation via prefrontal and motor cortex functional connectivity may also contribute, though direct immunological mechanistic evidence in hayfever specifically remains preliminary.

---

How effective are anti-IgE biologics (omalizumab) for severe allergic rhinitis?

What the research says

Omalizumab demonstrates consistent clinical efficacy for severe and seasonal allergic rhinitis inadequately controlled by standard therapies, with multiple RCTs and meta-analyses showing significant reductions in total nasal symptom scores, improved rhinoconjunctivitis quality of life, and reduced rescue medication use compared to placebo plus standard-of-care. A 2021 systematic review and meta-analysis of RCTs (Tsabouri et al.) and a 2019 meta-analysis (Yu et al.) both confirm these benefits, and real-world data corroborate meaningful symptom relief across diverse patient populations including those with asthma comorbidity. The safety profile appears favorable with no unexpected adverse signals reported across trials.

How it works

Omalizumab binds circulating free IgE, preventing its attachment to high-affinity FcεRI receptors on mast cells, basophils, and dendritic cells, thereby blocking allergen-triggered degranulation, histamine release, and downstream Th2 cytokine production (IL-4, IL-5, IL-13) that drive nasal mucosal inflammation in AR. This interruption of the IgE-mediated inflammatory cascade attenuates both early- and late-phase nasal allergic responses in a dose-dependent manner.

---

What novel immunotherapy approaches (epicutaneous, intralymphatic) are in clinical trials for hayfever?

What the research says

Intralymphatic immunotherapy (ILIT) has demonstrated promising efficacy and safety for pollen-induced allergic rhinitis in several small-to-moderate RCTs, with a compressed dosing schedule of only 3 injections over 3 months compared to years of conventional subcutaneous immunotherapy (SCIT). Epicutaneous immunotherapy (EPIT) for hayfever remains largely investigational, with most evidence derived from preclinical work or food allergy models rather than completed pollen-specific trials. Both approaches are positioned as patient-friendly alternatives to SCIT, but robust Phase III data with direct SCIT comparisons for seasonal allergic rhinitis are still lacking.

How it works

ILIT delivers allergen directly into inguinal lymph nodes under ultrasound guidance, exploiting the high concentration of antigen-presenting cells and T-regulatory cell priming sites to induce tolerance more efficiently with far lower total allergen doses. EPIT leverages the skin's dense network of Langerhans cells and dermal dendritic cells, which are thought to preferentially drive tolerogenic rather than sensitizing immune responses upon epicutaneous allergen exposure.